RIPAMONTI, FRANCESCO
RIPAMONTI, FRANCESCO
DIPARTIMENTO DI SCIENZE MEDICHE (attivo dal 01/01/2000 al 27/04/2012)
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
2014 M.G. Della Porta, E.P. Alessandrino, A. Bacigalupo, M.T. Van Lint, L. Malcovati, C. Pascutto, M. Falda, M. Bernardi, F. Onida, S. Guidi, A.P. Iori, R. Cerretti, P. Marenco, P. Pioltelli, E. Angelucci, R. Oneto, F. Ripamonti, P. Bernasconi, A. Bosi, M. Cazzola, A. Rambaldi
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
2013 E.P. Alessandrino, M.G.D. Porta, L. Malcovati, C.H. Jackson, C. Pascutto, A. Bacigalupo, M. Teresa van Lint, M. Falda, M. Bernardi, F. Onida, S. Guidi, A.P. Iori, R. Cerretti, P. Marenco, P. Pioltelli, E. Angelucci, R. Oneto, F. Ripamonti, A. Rambaldi, A. Bosi, M. Cazzola
Conjunctival hemorrhagic events associated with imatinib
2007 F. Radaelli, C. Vener, F. Ripamonti, A. Iurlo, M. Colombi, A. Artoni, G. Reda, G. Lambertenghi Deliliers
Low dose dasatinib in refractory imatinib mesylate chronic myeloid leukemia : case report
2007 F. Radaelli, G. Reda, F. Ripamonti, A. Gardellini, C. Vener, G. Lambertenghi Deliliers
Role of dasatinib in PH '-positive acute lymphoblastic leukemia (ALL) after imatinib-based therapy failure : a case report
2007 A. Cortelezzi, M.C. Pasquini, F. Radaelli, G. Reda, F. Ripamonti, A. Gardellini, D. Intini, O. Spinelli, G. Lambertenghi Deliliers
Abnormal clones in Philadelphia negative (Ph-) cells in CML patients treated with Imatinib mesylate
2007 M.G. Grimoldi, F. Radaelli, A Benevento, S. Buiatiotis, R. Busuito, A. Iurlo, R. Malgara, C. Vener, F. Ripamonti, M. R. Sansò
Conjunctival hemorrhagic events associated with imatinib mesylate
2007 F. Radaelli, C. Vener, F. Ripamonti, A. Iurlo, M. Colombi, A. Artoni, G. Reda, G. Lambertenghi Deliliers
Low-dose ALEMTUZUMAB monotherapy in advanced chronic lymphocytic leukemia
2006 A. Cortelezzi, M.C. Pasquini, G. Reda, F. Ripamonti, B. Sarina, W. Barcellini, G. Lambertenghi Deliliers
Low dose campath 1-H is highly effective and safe in advanced chronic CLL
2006 A. Cortelezzi, M.C. Pasquini, U. Gianelli, B. Sarina, C. Vener, G. Reda, F. Ripamonti, L. Nobili, G. Lambertenghi Deliliers
Fludarabine-Ifosfamide-Rituximab (FIR): a therapeutic option for chronic lymphocytic leukemia patients resistant to Chlorambucil
2006 A. Cortelezzi, M. Pasquini, G. Reda, F. Ripamonti, D. G Lambertenghi